Literature DB >> 12619915

Helplessness and escape performance: glutamate-adenosine interactions in the frontal cortex.

Aimee M Hunter1, Bernard W Balleine, Thomas R Minor.   

Abstract

Adenosine has been implicated as a proximate mediator of escape deficits in the learned helplessness paradigm, suggesting that neuronal overactivation-a typical precursor to adenosine release-precedes the inescapable shock-induced impairment (T. R. Minor, W. C. Chang, & J. L. Winslow, 1994). In the present experiments, glutamate (100 microg) injection into the rat frontal cortex produced a deficit in escape performance. Pretest treatment with the adenosine receptor antagonist caffeine (7 mg/kg ip) reversed the effect of glutamate when infused 1 hr. but not 72 hr, after glutamate injection. Finally, microinjection of 2-amino-5-phosphonovaleric acid (5 ng) into the frontal cortex prior to inescapable shock prevented the escape deficit. These findings are consistent with the involvement of N-methyl-D-aspartate receptor activation in the frontal cortex in the helplessness effect.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12619915     DOI: 10.1037//0735-7044.117.1.123

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN: 0735-7044            Impact factor:   1.912


  12 in total

1.  Post-learning infusion of anisomycin into the anterior cingulate cortex impairs instrumental acquisition through an effect on reinforcer valuation.

Authors:  Sietse Jonkman; Barry J Everitt
Journal:  Learn Mem       Date:  2009-10-28       Impact factor: 2.460

2.  Early-life stress induces EAAC1 expression reduction and attention-deficit and depressive behaviors in adolescent rats.

Authors:  Han-Byeol Kim; Ji-Young Yoo; Seung-Yeon Yoo; Sang Won Suh; Seoul Lee; Ji Hye Park; Jun-Ho Lee; Tai-Kyoung Baik; Hye-Sun Kim; Ran-Sook Woo
Journal:  Cell Death Discov       Date:  2020-08-08

3.  Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study.

Authors:  Eric J Lenze; Elizabeth R Skidmore; Amy E Begley; John W Newcomer; Meryl A Butters; Ellen M Whyte
Journal:  Int J Geriatr Psychiatry       Date:  2011-12-16       Impact factor: 3.485

Review 4.  Cytokine-purine interactions in behavioral depression in rats.

Authors:  Thomas R Minor; Qingjun Huang; Elizabeth A Foley
Journal:  Integr Physiol Behav Sci       Date:  2003 Jul-Sep

5.  Adenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognition.

Authors:  Hai-Ying Shen; Jiang-Fan Chen
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

Review 6.  Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders.

Authors:  Rodrigo A Cunha; Sergi Ferré; Jean-Marie Vaugeois; Jiang-Fan Chen
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

7.  Brain network reorganization differs in response to stress in rats genetically predisposed to depression and stress-resilient rats.

Authors:  N Gass; R Becker; A J Schwarz; W Weber-Fahr; C Clemm von Hohenberg; B Vollmayr; A Sartorius
Journal:  Transl Psychiatry       Date:  2016-12-06       Impact factor: 6.222

Review 8.  Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression.

Authors:  Laura López-Cruz; John D Salamone; Mercè Correa
Journal:  Front Pharmacol       Date:  2018-06-01       Impact factor: 5.810

9.  The Role of Astroglia in the Antidepressant Action of Deep Brain Stimulation.

Authors:  Adeline Etiévant; Guillaume Lucas; Ouria Dkhissi-Benyahya; Nasser Haddjeri
Journal:  Front Cell Neurosci       Date:  2016-01-12       Impact factor: 5.505

10.  8-Cyclopentyl-1,3-dimethylxanthine enhances effectiveness of antidepressant in behavioral tests and modulates redox balance in the cerebral cortex of mice.

Authors:  Mariola Herbet; Aleksandra Szopa; Anna Serefko; Sylwia Wośko; Monika Gawrońska-Grzywacz; Magdalena Izdebska; Iwona Piątkowska-Chmiel; Paulina Betiuk; Ewa Poleszak; Jarosław Dudka
Journal:  Saudi Pharm J       Date:  2018-02-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.